Drug Profile
ETBX 011
Alternative Names: Ad5 [E1-, E2B-]-CEA; AD5 CEA vaccine; Ad5[E1-,E2b-]-CEA vaccine; Adenoviral CEA vaccine; CEA-targeted vaccine - Etubics; ETBX-011Latest Information Update: 28 Feb 2023
Price :
$50
*
At a glance
- Originator Etubics Corporation
- Developer Etubics Corporation; ImmunityBio; National Cancer Institute (USA)
- Class Cancer vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Colorectal cancer; Pancreatic cancer; Solid tumours; Triple negative breast cancer
- No development reported Liver cancer
Most Recent Events
- 28 Feb 2023 No recent reports of development identified for phase-I development in Solid-tumours(Combination therapy, Late-stage disease, Second-line therapy or greater) in USA (SC, Injection)
- 09 Mar 2021 NantKwest has been merged with ImmunityBio to form ImmunityBio
- 24 Feb 2021 No development reported - Phase-I/II for Liver cancer (Combination therapy, Inoperable/Unresectable, Late-stage disease, Second-line therapy or greater) in USA (SC)